INTRODUCTION
Approximately 25,000 allogeneic hematopoietic stem cell transplants (HSCTs) are performed annually. Cutaneous complications are common and include a spectrum of acute and chronic graft-versus-host disease (GVHD). Mechanisms implicated in the rare development of sarcoidosis after HSCT include specific pretransplant conditioning regimens, possible donor-to-recipient transmission, genetic predisposition of sarcoidosis, and post-HSCT immune dysregulation.
REPORT OF A CASE
A 58-year-old woman with a history of polymyalgia rheumatica, myelofibrosis (27 months postallogeneic HSCT from her human leukocyte antigen [HLA]-matched brother), hypothyroidism, GVHD of the gut, and noncaseating granulomas on lung biopsy, presented with the following new skin findings: white, firm lesions under her breasts (Fig 1) and an increasing number of asymptomatic red scaly bumps on her bilateral forearms and trunk (Fig 2) . The lesions persisted despite use of triamcinolone 0.1% ointment. She denied family history of skin or lung disease. Her medications included omeprazole, vitamin D, calcium, duloxetine, levothyroxine, and alprazolam as needed. Importantly, she had not received any immunosuppressive therapy for almost 1 year.
Physical examination found bilateral inframammary white atrophic plaques and erythematous-to- 
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DISCUSSION
In 2014, the National Institutes of Health proposed updated diagnostic requirements for chronic GVHD, none of which include granulomatous phenomenon. 1 Thorough literature review found 9 cases of sarcoidosis after allogeneic HSCT, all reported in nondermatologic literature (Table I) . [2] [3] [4] [5] [6] [7] [8] [9] Five of the 9 cases describe cutaneous findings, 4 of which had cutaneous biopsies showing noncaseating granulomas. An additional 5 cases of sarcoidosis have been reported after autologous HSCT. 10 Immune dysregulation, both donor derived and de novo, after allogeneic HSCT is postulated to provide the immunologic environment necessary for the development of sarcoidosis. Additionally, 2 reported cases have confirmed donor-derived sarcoidosis with chimerism analysis of sarcoidal lesions. 5, 9 Genetic predisposition to sarcoidosis is well established and frequently associated with HLA types A1, B8, and DR3. Acute disease with good prognosis is associated with HLA types DRB1*0301 and DQB1*0201, whereas prolonged disease course with poor prognosis is associated with DRB1*1501 and DRB1*0602. 11 Our patient and her healthy donor possess these 2 poor-prognostic HLA types. One of the donors in the 9 previously reported cases had sarcoidosis after the marrow donation, whereas 2 of the 9 had sarcoidosis diagnosed before the donation. Based on these findings, our patient's donor may be at an increased risk for sarcoidosis.
Immune dysregulation after HSCT is well known to manifest as a variety of forms of GVHD. Because sarcoidosis is also attributed to immune dysregulation, it is not surprising that this common granulomatous dermatitis may be seen with increased frequency after HSCT. Our case shows the simultaneous presentation of chronic GVHD in the form of lichen sclerosus and new-onset sarcoidosis after HSCT. Dermatologists should add sarcoidosis to the list of possible posttransplant cutaneous eruptions, especially in patients with susceptible HLA types. Further research including analysis of specific HLA types, information always available in the transplant population, may lead to a better understanding of the risk factors and pathogenesis of this granulomatous conundrum.
